Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Myeloid Leukaemia

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

Bone Marrow Transplantation volume 30, pages 23–28 (2002)Cite this article

Abstract

Gemtuzumab ozogamicin (GO) (Mylotarg, CMA-676) is a novel chemotherapeutic agent consisting of an anti-CD33 monoclonal antibody linked to calicheamicin, and is associated with a 30% response rate in patients with CD33-positive acute myeloid leukemia (AML) in first relapse. GO therapy has a 20% incidence of grade 3 or 4 hepatotoxicity, and has recently been associated with hepatic veno-occlusive disease (VOD). The efficacy and toxicity of GO in patients with AML who have relapsed after hematopoietic stem cell transplant (HSCT) is unknown, as this population was largely excluded from phase II studies. We reviewed the outcomes of eight consecutive patients with AML who received GO following relapse after HSCT. Two (25%) had responses to GO. One patient, who had had two previous HSCT and prior hyperbilirubinemia, developed severe VOD and died 14 days after GO therapy. The other seven patients did not meet diagnostic criteria for VOD. We conclude that GO can be safe and effective in patients who relapse following HSCT, but that caution is warranted in patients with multiple risk factors for VOD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia New Engl J Med 1999 341: 1051 1062

    Article  CAS  Google Scholar 

  2. Webb D . Management of relapsed acute myeloid leukaemia Br J Haematol 1999 106: 851 859

    Article  CAS  Google Scholar 

  3. Levy V, Marjanovic Z, Vekhoff A et al. Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years Am J Hematol 2000 64: 232 233

    Article  CAS  Google Scholar 

  4. Dinndorf P, Andrews R, Benjamin D et al. Expression of normal myeloid–associated antigens by acute leukemia cells Blood 1986 67: 1048 1053

    CAS  Google Scholar 

  5. Sievers E, Appelbaum F, Speilberger R et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678 3684

    CAS  Google Scholar 

  6. Sievers E, Larson R, Stadtmauer E et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 2001 19: 3244 3254

    Article  CAS  Google Scholar 

  7. Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation Blood 1998 92: 3599 3604

    CAS  Google Scholar 

  8. Bearman S . Veno-occlusive disease of the liver Curr Opin Oncol 2000 12: 103 109

    Article  CAS  Google Scholar 

  9. Richardson P, Guinan E . The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches Br J Haematol 1999 107: 485 493

    Article  CAS  Google Scholar 

  10. Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation Eur J Haematol 2000 64: 281 291

    Article  CAS  Google Scholar 

  11. Bearman S, Lee J, Baron A et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients Blood 1997 89: 1501 1506

    CAS  Google Scholar 

  12. Richardson P, Elias D, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in efficacy without significant toxicity in a high risk population Blood 1998 4: 142 150

    Google Scholar 

  13. Barclay KL, Yeong ML . Actinomycin D associated hepatic veno-occlusive disease — a report of 2 cases Pathology 1994 26: 257 260

    Article  CAS  Google Scholar 

  14. Ortega JA, Donaldson SS, Ivy SP et al. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma Cancer 1997 79: 2435 2439

    Article  CAS  Google Scholar 

  15. Gill RA, Onstad GR, Cardamone JM et al. Hepatic veno-occlusive disease caused by 6-thioguanine Ann Intern Med 1982 96: 58 60

    Article  CAS  Google Scholar 

  16. Neumeister P, Eibl M, Zinke-Cerwenka W et al. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate Ann Hematol 2001 80: 119 120

    Article  CAS  Google Scholar 

  17. McDonald G, Hinds M, Fisher L et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255 267

    Article  CAS  Google Scholar 

  18. Sievers E, Larson R, Estey E et al. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): relationship to hematopoietic stem cell transplantation Blood 2000 96: 206b

    Google Scholar 

  19. Giles F, Kantarjian H, Kornblau S et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Cancer 2001 92: 406 413

    Article  CAS  Google Scholar 

  20. Smith JW . Tolerability and side-effect profile of rhIL-11 Oncology 2000 14 (9 Suppl. 8): 41 47

    Google Scholar 

  21. Gordon MS, McCaskill-Stevens WJ, Battiato LA et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy Blood 1996 87: 3615 3624

    CAS  PubMed  Google Scholar 

  22. Hasegawa S, Horibe K, Kawabe T et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors Bone Marrow Transplant 1998 22: 1191 1197

    Article  CAS  Google Scholar 

  23. Gilles J, Divon M, Bentolila E et al. Immunophenotypic characterization of human fetal liver hematopoietic stem cells during the midtrimester of gestation Am J Obstet Gynecol 1997 177: 619 625

    Article  CAS  Google Scholar 

  24. Blakolmer K, Jaskiewicz K, Dunsford H et al. Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver Hepatology 1995 21: 1510 1516

    Article  CAS  Google Scholar 

  25. Muench M, Cupp J, Polakoff J et al. Expression of CD33, CD38, and HLA-DR on CD34+ human fetal liver progenitors with a high proliferative potential Blood 1994 83: 3170 3181

    CAS  Google Scholar 

  26. Favaloro E . Differential expression of surface antigens on activated endothelium Immunol Cell Biol 1993 71: 571 581

    Article  CAS  Google Scholar 

  27. Applebaum F . Antibody-targeted therapy for myeloid leukemia Sem Hematol 1999 36: (Suppl. 6) 2 8

    Google Scholar 

  28. Caron P, Schwartz M, Sung Co M et al. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia Cancer 1994 73: (Suppl.) 1049 1056

    Article  CAS  Google Scholar 

  29. Jurcic J, Caron P, Nikula T et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 1995 55: (Suppl.) 5908s 5910s

    CAS  Google Scholar 

  30. Stadtmauer EA, Larson R, Sievers E et al. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676) Blood 2001 98: 124a

    Google Scholar 

  31. Zein N, Sinha AM, McGahren WJ et al. Calicheamicin γI1: an antitumor antibiotic that cleaves double-stranded DNA site specifically Science 1988 240: 1198 1201

    Article  CAS  Google Scholar 

  32. Larson RA . Current use and future development of gemtuzumab ozogamicin Semin Hematol 2001 38: (Suppl. 6) 24 31

    Article  CAS  Google Scholar 

  33. Gillespie AM, Broadhead TJ, Chan SY et al. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer Ann Oncol 2000 11: 735 741

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematologic Malignancies Program and the Bone Marrow and Stem Cell Transplantation Program, University of Pennsylvania Cancer Center, Philadelphia, PA, USA

    AD Cohen, SM Luger, C Sickles, PA Mangan, DL Porter, SJ Schuster, DE Tsai, S Nasta, AM Gewirtz & EA Stadtmauer

Authors
  1. AD Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SM Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Sickles
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. PA Mangan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. DL Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. SJ Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. DE Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Nasta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. AM Gewirtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. EA Stadtmauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, A., Luger, S., Sickles, C. et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30, 23–28 (2002). https://doi.org/10.1038/sj.bmt.1703602

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703602

Keywords

This article is cited by

Search

Advanced search

Quick links